Live feed11:26:31·20mANALYSTRatingvia QuantisnowLeerink Partners resumed coverage on Larimar Therapeutics with a new price targetByQuantisnow·Wall Street's wire, on your screen.LRMR· Larimar Therapeutics Inc.Health CareOriginal source